All News

Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.

Men with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy experienced an improved, long-lasting overall survival compared with those who received placebo.

Patients who were treated with ramucirumab plus gemcitabine experienced improved overall survival compared with patients treated with gemcitabine plus placebo.

Patients with solid tumors and an NTRK gene fusion who experienced progressive disease appear to derive benefit from repotrectinib, which received a breakthrough therapy designation from the FDA.

Patients with metastatic urothelial carcinoma did not derive further benefit from the addition of berzosertib to cisplatin and gemcitabine.

Continued overall survival improvement has been observed at landmark time points in patients with mantle cell lymphoma following treatment with autologous hemopoietic stem cell transplant.

Research of family registries found that individuals with a germline pathogenic ATM variant gene had greater lifetime risk of developing pancreatic cancer than individuals without the gene.

Patients with previously untreated metastatic uveal melanoma who also harbored HLA-A*02:01 and were treated with tebentafusp experienced a longer overall survival compared with the control group of a phase 3 clinical trial.

Adding venetoclax to cladribine, high-dose cytarabine, and idarubicin appears to yield high rates of minimal residual disease negativity and promising survival in patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Patients with unresectable or metastatic HER2-positive breast cancer who have received one or more HER2-targeting agents in prior lines of therapy may benefit from treatment with fam-trastuzumab deruxtecan-nxki, which received a breakthrough therapy designation from the FDA.

The FDA granted priority review to 177Lu-PSMA-617 in pretreated metastatic castration-resistant prostate cancer based on positive survival data from the phase 3 VISION study.

Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.

The FDA has approved the use of CD19-directed CAR T-cell therapy brexucabtagene autoleucel for adult patients with relapsed/refractory precursor acute lymphoblastic leukemia.

Treatment with nivolumab/ipilimumab and nivolumab/chemotherapy has demonstrated efficacy in unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, with results from the CheckMate-648 trial leading to the acceptance of the regimens’ applications by the FDA.

Investigators believe that active monitoring presents an alternative option to capecitabine maintenance therapy for patients with stable or responding metastatic colorectal cancer.

An association was identified between second-line clinical trial participation for patients with metastatic non–small cell lung cancer and a mean cost savings of $6663 for health care payers.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how he would like to see the OCEAN trial and Melflufen progress for relapsed/refractory multiple myeloma.

Patients with early breast cancer appear to have consistent prognostic value associated with residual cancer burden, regardless of disease subtype.

The addition of docetaxel did not improve overall survival for patients with nonmetastatic unfavorable-risk prostate cancer, although it reduced incidence rates of radiation therapy-induced cancer.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most common adverse effects experienced from the quadruplet drug treatment for patients with multiple myeloma.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss the differences in safety profiles between melflufen/dexamethasone and pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Multimedia intervention Starting the Conversation successfully encouraged discourse about sexual health among patients with breast cancer and reduced anxiety.

The association between current human papillomavirus vaccination trends and incidence of oropharynx cancer will be modest over the next 25 years.

As more novel therapeutic targets are discovered in patients with chronic lymphocytic leukemia, the more possibilities are presented in terms of treatment with targeted agents, small molecules, and cellular therapies.

Patients with muscle-invasive bladder cancer treated with gemcitabine and split-dose cisplatin plus pembrolizumab experienced improved pathological downstaging.

A final overall survival analysis found improved results and a tolerable safety profile for patients with advanced IDH1-mutated cholangiocarcinoma who received ivosidenib vs placebo.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.

Refractory gastrointestinal stromal tumors can potentially be treated by using a KIT inhibitor combination of PLX9486 and sunitinib.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma.

A recent trial found that patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer with prior disease control on standard EGFR inhibitors demonstrated efficacy and tolerability of mobocertinib.